Novelle Marta G, Wahl Devin, Diéguez Carlos, Bernier Michel, de Cabo Rafael
Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA; Research Center of Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela 15782, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Santiago de Compostela 15706, Spain.
Translational Gerontology Branch, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
Ageing Res Rev. 2015 May;21:1-15. doi: 10.1016/j.arr.2015.01.002. Epub 2015 Jan 24.
Pre-clinical findings have provided mounting evidence that resveratrol, a dietary polyphenol, may confer health benefits and protect against a variety of medical conditions and age-related complications. However, there is no consistent evidence of an increased protection against metabolic disorders and other ailments when comparing studies in laboratory animals and humans. A number of extraneous and potential confounding variables can affect the outcome of clinical research. To date, most of the studies that have investigated the effect of resveratrol administration on patient outcomes have been limited by their sample sizes. In this review, we will survey the latest advances regarding the timing, dosage, formulation, bioavailability, toxicity of resveratrol, and resveratrol-drug interactions in human studies. Moreover, the present report focuses on the actions of resveratrol treatment in combating diseases, such as cancer, diabetes, neurodegeneration, cardiovascular disease, and other age-related ailments.
临床前研究结果提供了越来越多的证据表明，白藜芦醇这种膳食多酚可能具有健康益处，并能预防多种疾病和与年龄相关的并发症。然而，在比较实验室动物和人类研究时，并没有一致的证据表明其对代谢紊乱和其他疾病的预防作用增强。许多外在的和潜在的混杂变量会影响临床研究的结果。迄今为止，大多数研究白藜芦醇给药对患者预后影响的研究都受到样本量的限制。在本综述中，我们将探讨人类研究中关于白藜芦醇的给药时间、剂量、剂型、生物利用度、毒性以及白藜芦醇与药物相互作用的最新进展。此外，本报告重点关注白藜芦醇治疗在对抗癌症、糖尿病、神经退行性疾病、心血管疾病和其他与年龄相关疾病等方面的作用。
